Biocad eliminated the pain.
Biocad has registered a new form of the biological drug Delibera (adlimumab): the concentration has been doubled - 40 mg is now in 0.4 ml instead of 0.8 ml, citrate has been removed from the composition, which reduces the pain of injection. Bioequivalence was confirmed in study BCD-057-5 in 443 healthy volunteers.
"Innovation" in this case is removing something that caused pain from the syringe and calling it a breakthrough in drug development. In fact, it is a cosmetic improvement of the old adlimumab under a new round of patent protection and marketing "now it doesn't hurt at all to inject". Domestic import substitution at its best: bioequivalence in healthy volunteers, not clinical results in real patients.
Of course, for long-term IBD/rheumatology patients, the injection volume is smaller and the absence of citrate actually reduces discomfort - a small thing, but with daily/weekly treatment for years it has cumulative importance.